Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.VentiRx Pharmaceuticals has initiated a Phase I clinical trial of VTX-1463, a selective intranasal toll-like receptor 8 agonist for the treatment of allergic rhinitis.
Subscribe to our email newsletter
The objectives of this trial will be to assess safety, tolerability and pharmacokinetics of single and multiple ascending doses of VTX-1463 in approximately 30 healthy volunteers. The trial is being conducted in the Netherlands.
Robert Hershberg, chief medical officer of VentiRx, said: “We are pleased to advance VTX-1463 into the clinic. This is another milestone for our toll-like receptor 8 effort as this is the second clinical program initiated in the last six months.”